DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Geyer CE, Huang C-S, Mano MS. et al.
Phase III Study of Trastuzumab Emtansine (T-DM1) vs. Trastuzumab as Adjuvant Therapy in Patients with HER2-positive Early Breast Cancer with Residual Invasive disease after Neoadjuvant Chemotherapy and HER2-Targeted Therapy Including Trastuzumab: Primary Results from KATHERINE. SABCS 2018. San Antonio/Texas/USA, Dezember 2018. Oral presentation GS1-10.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.